Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which … Read more
Market Cap & Net Worth: Telix Pharmaceuticals Limited (TLX)
Telix Pharmaceuticals Limited (NASDAQ:TLX) has a market capitalization of $3.08 Billion ($3.08 Billion) as of March 30, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4290 globally and #2709 in its home market, demonstrating a 7.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Telix Pharmaceuticals Limited's stock price $9.20 by its total outstanding shares 334724485 (334.72 Million).
Telix Pharmaceuticals Limited Market Cap History: 2015 to 2026
Telix Pharmaceuticals Limited's market capitalization history from 2015 to 2026. Data shows change from $7.13 Billion to $3.08 Billion (-6.29% CAGR).
Index Memberships
Telix Pharmaceuticals Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.16 Trillion | 0.12% | #110 of 976 |
|
NASDAQ Composite
IXIC
|
$31.22 Trillion | 0.01% | #525 of 3165 |
Weight: Telix Pharmaceuticals Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Telix Pharmaceuticals Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Telix Pharmaceuticals Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.08x
Telix Pharmaceuticals Limited's market cap is 2.08 times its annual revenue
1758.53x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $7.02 Billion | $29.40 Million | -$44.00K | 238.82x | N/A |
| 2017 | $13.22 Billion | $31.77 Million | -$6.38 Million | 416.28x | N/A |
| 2018 | $187.45 Million | $195.14K | -$13.83 Million | 960.56x | N/A |
| 2024 | $5.15 Billion | $783.21 Million | $49.92 Million | 6.58x | 103.26x |
| 2025 | $2.51 Billion | $1.21 Billion | -$10.69 Million | 2.08x | N/A |
Competitor Companies of TLX by Market Capitalization
Companies near Telix Pharmaceuticals Limited in the global market cap rankings as of March 30, 2026.
Key companies related to Telix Pharmaceuticals Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #173 globally with a market cap of $109.64 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #282 globally with a market cap of $72.69 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #338 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #491 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #173 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.64 Billion | $433.07 |
| #282 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.69 Billion | $737.71 |
| #338 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #491 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Telix Pharmaceuticals Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Telix Pharmaceuticals Limited's market cap moved from $7.13 Billion to $ 3.08 Billion, with a yearly change of -6.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.08 Billion | +22.83% |
| 2025 | $2.51 Billion | -51.36% |
| 2024 | $5.15 Billion | +2650.00% |
| 2018 | $187.45 Million | -98.58% |
| 2017 | $13.22 Billion | +88.32% |
| 2016 | $7.02 Billion | -1.50% |
| 2015 | $7.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 29th, 2026 the market cap of Telix Pharmaceuticals Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.08 Billion USD |
| MoneyControl | $3.08 Billion USD |
| MarketWatch | $3.08 Billion USD |
| marketcap.company | $3.08 Billion USD |
| Reuters | $3.08 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.